Trevi Therapeutics, Inc. (NASDAQ:TRVI) is expected to report second quarter earnings results, after market close, on Thursday 13th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.48 per share.
Looking ahead, the full year loss are expected at $ 1.92 per share.
Stock Performance
According to the previous trading day, closing price of TRVI was $ 6.60, representing a 396.24 % increase from the 52 week low of $ 1.33 and a 22.35 % decrease over the 52 week high of $ 8.50.
The company has a market capital of $ 117.77 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 13th July 2020, maintained by Needham & Company LLC at Buy rating, with $ 12.00 target price.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The companys nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinsons disease. Trevi Therapeutics, Inc.
